Clementia Pharmaceuticals Inc (CMTA) Given Consensus Rating of “Buy” by Analysts

Clementia Pharmaceuticals Inc (NASDAQ:CMTA) has received a consensus rating of “Buy” from the seven analysts that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $23.00.

Several analysts have recently issued reports on CMTA shares. Zacks Investment Research cut shares of Clementia Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday. Bloom Burton reaffirmed a “buy” rating on shares of Clementia Pharmaceuticals in a research report on Sunday, December 16th. Finally, Robert W. Baird started coverage on shares of Clementia Pharmaceuticals in a research report on Friday, January 18th. They set an “outperform” rating and a $24.00 price objective for the company.

Shares of CMTA stock traded up $0.09 during midday trading on Friday, reaching $14.09. 300 shares of the company traded hands, compared to its average volume of 34,927. Clementia Pharmaceuticals has a 1-year low of $8.10 and a 1-year high of $19.58. The company has a market cap of $444.08 million, a price-to-earnings ratio of -1.76 and a beta of -0.05.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Baker BROS. Advisors LP grew its holdings in Clementia Pharmaceuticals by 62.1% during the 3rd quarter. Baker BROS. Advisors LP now owns 1,933,624 shares of the company’s stock valued at $21,560,000 after buying an additional 741,029 shares in the last quarter. NEA Management Company LLC raised its stake in Clementia Pharmaceuticals by 26.4% in the fourth quarter. NEA Management Company LLC now owns 2,707,734 shares of the company’s stock valued at $31,843,000 after buying an additional 566,037 shares in the last quarter. Artal Group S.A. raised its stake in Clementia Pharmaceuticals by 246.0% in the third quarter. Artal Group S.A. now owns 692,000 shares of the company’s stock valued at $7,716,000 after buying an additional 492,000 shares in the last quarter. Fosun International Ltd acquired a new stake in Clementia Pharmaceuticals in the fourth quarter valued at $2,627,000. Finally, JPMorgan Chase & Co. raised its stake in Clementia Pharmaceuticals by 17.6% in the third quarter. JPMorgan Chase & Co. now owns 1,037,047 shares of the company’s stock valued at $11,563,000 after buying an additional 155,336 shares in the last quarter. 76.81% of the stock is owned by institutional investors and hedge funds.

About Clementia Pharmaceuticals

Clementia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, develops treatments for patients suffering from bone disorders and other diseases. Its lead product candidate is palovarotene, an oral small molecule for the treatment of fibrodysplasia ossificans progressive, multiple osteochondromas, dry eye disease, and other diseases is in the Phase 3 MOVE Trial.

Further Reading: What is the quiet period?

Analyst Recommendations for Clementia Pharmaceuticals (NASDAQ:CMTA)

Receive News & Ratings for Clementia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clementia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit